Bank of New York Mellon’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-201,957
| Closed | -$1.94M | – | 4204 |
|
|
2024
Q4 | $1.94M | Buy |
201,957
+37,856
| +23% | +$198K | ﹤0.01% | 2773 |
|
|
2024
Q3 | $469K | Sell |
164,101
-64,599
| -28% | -$200K | ﹤0.01% | 3557 |
|
|
2024
Q2 | $668K | Buy |
228,700
+26,316
| +13% | +$72K | ﹤0.01% | 3411 |
|
|
2024
Q1 | $646K | Sell |
202,384
-27,576
| -12% | -$91.9K | ﹤0.01% | 3376 |
|
|
2023
Q4 | $773K | Buy |
229,960
+18,663
| +9% | +$48.1K | ﹤0.01% | 3327 |
|
|
2023
Q3 | $503K | Sell |
211,297
-436
| -0.2% | -$914 | ﹤0.01% | 3541 |
|
|
2023
Q2 | $373K | Buy |
211,733
+162,950
| +334% | +$416K | ﹤0.01% | 3740 |
|
|
2023
Q1 | $150K | Hold |
48,783
| – | – | ﹤0.01% | 4001 |
|
|
2022
Q4 | $259K | Sell |
48,783
-685
| -1% | -$3.13K | ﹤0.01% | 3860 |
|
|
2022
Q3 | $175K | Buy |
49,468
+31,910
| +182% | +$106K | ﹤0.01% | 4063 |
|
|
2022
Q2 | $45K | Sell |
17,558
-84,491
| -83% | -$235K | ﹤0.01% | 4368 |
|
|
2022
Q1 | $457K | Sell |
102,049
-1,790
| -2% | -$8.07K | ﹤0.01% | 3761 |
|
|
2021
Q4 | $707K | Buy |
103,839
+2,451
| +2% | +$16.7K | ﹤0.01% | 3584 |
|
|
2021
Q3 | $739K | Buy |
101,388
+18,488
| +22% | +$159K | ﹤0.01% | 3578 |
|
|
2021
Q2 | $830K | Buy |
82,900
+19,800
| +31% | +$177K | ﹤0.01% | 3529 |
|
|
2021
Q1 | $603K | Buy |
63,100
+33,519
| +113% | +$329K | ﹤0.01% | 3587 |
|
|
2020
Q4 | $324K | Buy |
29,581
+6,289
| +27% | +$66.3K | ﹤0.01% | 3794 |
|
|
2020
Q3 | $206K | Buy |
+23,292
| New | +$265K | ﹤0.01% | 3842 |
|
Other funds holding PSTX
Bank of New York Mellon's PSTX Position: Q1 2025 in Review
Bank of New York Mellon sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 201,957 shares — an estimated $1.94M sold.
Bank of New York Mellon first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $1.94M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Bank of New York Mellon reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Bank of New York Mellon sold 201,957 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.94M.
- Bank of New York Mellon first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Bank of New York Mellon's Poseida Therapeutics, Inc. Common Stock position peaked at $1.94M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Bank of New York Mellon's 13F filing for Q1 2025, filed 29 Apr 2025.